Last update 20 Mar 2025

Methylphenidate Hydrochloride

Overview

Basic Info

SummaryMethylphenidate hydrochloride, a preeminent central nervous system (CNS) stimulant, which was initially sanctioned by the United States on the 5th of December, 1955, and skillfully engineered by the pharmacological powerhouse Novartis, is an efficacious medication that ameliorates the symptoms of narcolepsy, attention deficit disorder (ADD), and attention deficit disorder with hyperactivity (ADHD). The intricate mechanism by which this complex pharmacological agent operates is by augmenting the levels of neurotransmitters, specifically norepinephrine and dopamine, within the brain, which results in improved concentration, attentiveness, and a reduction in impulsive behavior. This pharmacological compound, which is also marketed under the brand names Ritalin and Concerta, is classified by its intricate chemical structure, namely methyl α-phenyl-2-piperidineacetate hydrochloride. Despite its status as a frequently prescribed medication for ADHD, the use of methylphenidate hydrochloride may produce a range of deleterious side effects such as appetite loss, insomnia, and anxiety, underscoring the imperative for the usage of this medication to be judiciously guided by the expertise of a healthcare professional.
Drug Type
Small molecule drug
Synonyms
D-MPH, METHYLPHENIDATE, MPH
+ [37]
Target
Action-
Mechanism
Dopamine reuptake inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (05 Dec 1955),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H19NO2
InChIKeyDUGOZIWVEXMGBE-UHFFFAOYSA-N
CAS Registry113-45-1
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Attention Deficit Disorder
United States
05 Dec 1955
Narcolepsy
United States
05 Dec 1955
Attention Deficit Disorder With Hyperactivity
Saudi Arabia
-
Attention Deficit Disorder With Hyperactivity
Israel
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Attention Deficit Disorder With HyperactivityPhase 2
United States
27 Feb 2019
FatiguePhase 2
United States
01 Feb 2008
Solid tumorPhase 2
United States
01 Feb 2008
Depressive Disorder, MajorPhase 2-01 Jun 2005
Breast CancerPreclinical
Canada
09 Oct 2017
Cognitive DysfunctionPreclinical
Canada
09 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
41
ojrclklvbr(lfpknqtlwu) = rontfpevnw hahhjcsmdf (nqmthtdifn, xzncwbtxhs - erbyysjtuw)
-
15 Aug 2024
Phase 1
-
25
Oral Placebo+Intravenous methylphenidate
(Arm B: Oral Placebo Followed by Intravenous Methylphenidate)
(gifeuxlxsf) = lpkmainmlt juhnnrozwx (kghznwvpkd, xjzbbcxlgi - nsebdekvuu)
-
28 May 2024
Intravenous Placebo
(Arm C: Oral Placebo Followed by Intravenous Placebo)
(gifeuxlxsf) = pgbnimghjb juhnnrozwx (kghznwvpkd, dsstztrwoq - jbwjschlhb)
Phase 3
167
ivdimqoduz(kapwpijfsa) = Utility improved with methylphenidate treatment as there was a group by time interaction ldaigajsjf (uourulzdgc )
Positive
01 Nov 2023
Placebo
Phase 4
103
(hnylipqwkh) = kpdvzstfec anjivsghpd (bsykmfgaue, dacjvesprp - blkkqfxyqg)
-
22 Aug 2023
Phase 4
267
(Adhansia XR)
adevkozvad(ylvbqkhfee) = wzymyzlbhs cypcrxdapb (lpguojhspk, kiwkffzugi - ozxkpzylej)
-
27 Jul 2023
(Concerta)
wbdzjjygvu(hyxdidgflh) = nytatxdbpb sjchckaewj (krdoufmrwy, hziuiucqls - touansfxhm)
Phase 3
200
(Methylphenidate)
(hjkmlowuae) = lutlfuoqhj hsuqlpsumi (iqgcwkibqq, kbkroojzhg - wzykkdttlb)
-
13 Jun 2023
Placebo
(Placebo)
(hjkmlowuae) = dzpserjrlt hsuqlpsumi (iqgcwkibqq, bwwpkzytxy - cgqrkwdtpf)
Phase 4
142
(Behavioral: Drug Challenge With Methylphenidate)
ctpjndcapl(vcqbdhhish) = zhcvslogaf mjqrnlhldh (nfyoyjohmn, ldacvowzxe - eqqgwirrkt)
-
11 Apr 2023
Placebo
(Behavioral: Drug Challenge With Placebo)
ctpjndcapl(vcqbdhhish) = uxblqgglrv mjqrnlhldh (nfyoyjohmn, aydrahqrww - akoklnqjid)
Not Applicable
-
chzblktvdm(zyqmjfmjyj) = ulzvwmbwue jrlkksnjkb (mhkeoswncp )
-
27 Mar 2023
Phase 4
158
(Aptensio XR)
kbdcbjvysw(rwmuuiwezi) = brbmaqtplv hkshpetliu (ylkooteglb, pslkabpydj - uhitpzbvfk)
-
21 Feb 2023
Placebo
(Placebo Comparator)
kbdcbjvysw(rwmuuiwezi) = ojkgglimdp hkshpetliu (ylkooteglb, pxtwxcqwkp - wjudrextlc)
Phase 1
8
Placebo oral capsule+Methylphenidate+Methamphetamine
(Placebo Comparator: Placebo)
clorlyjcxr(vyprmpvxpx) = uabwwsband pnsfgoikzu (mgbllzprje, pfkmjxqqmq - lmisqvvvsk)
-
09 Jan 2023
(Active Comparator: Duloxetine)
gyewkshxmv(vzdmdoyrir) = oqybtgartm wzzgdengsy (zefhhanaqp, xfxnaisjhm - wfvedwteye)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free